Navigation Links
Camp High Harbour Response to Flu Outbreak Includes SpectraSan 24 Disinfectant
Date:7/16/2009

r camp directors inquiring about the product." -- Ken O'Kelley, Executive Director

"The EPA believes, based on available scientific information, that the currently registered Influenza A virus products will be effective against the 2009 H1N1 Flu Strain on hard, non-porous surfaces," stated Andrea Goren, executive director of North Canton, Ohio-based BioTech Medical. "However, only SpectraSan 24 has 24-hour residual efficacy and kills germs 20 times faster than traditional disinfectants on the market. It has the lowest toxicity rating assigned by the EPA, is non-corrosive, non-flammable, and is recommended for use in child care environments. It is EPA-registered and the first patented disinfectant in over 30 years."

"BioTech Medical is offering up to a 35% savings on any purchases of SpectraSan 24 through August 31, 2009," Goren added. "We are committed to helping adults and children across the country experience a happy and healthy summer."

To order product, or for additional information:
Andrea L. Goren
BioTech Medical LLC
phone: 800.284.9857 x 4260

About SpectraSan 24:
SpectraSan 24 is a new innovative broad-spectrum disinfectant (bactericidal, virucidal, and fungicidal) with 24-hour residual protection. SpectraSan 24 uses the advanced patented technology of SDC (Silver Dihydrogen Citrate) to kill 99.999% of germs more quickly and effectively than any other product on the market, while currently being the only registered disinfectant assigned the lowest toxicity rating (IV) by the EPA.

SpectraSan 24 is intended for use on hard non-porous surfaces in hospitals, nursing homes, correctional facilities, healthcare facilities, universities, grammar schools, middle schools, daycare centers, athletic facilities, community centers, office environments, cruise ships, airports, buses, metro liners, and other public places.

###

Read the full story at '/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

5

GOOD

Page: 1 2 3

Related medicine news :

1. Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbours Brands Contribute More Than $250,000 Worth of Exclusive Items
2. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
3. Study identifies key player in the bodys immune response to chronic stress
4. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
5. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
6. Merck & Co., Inc. Response to Todays New York Medicaid Suit
7. Maternal depression and controlling behavior associated with increased stress response in infants
8. Family history of alcoholism affects response to drug used to treat heavy drinking
9. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
10. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Camp High Harbour Response to Flu Outbreak Includes SpectraSan 24 Disinfectant
Camp High Harbour Response to Flu Outbreak Includes SpectraSan 24 Disinfectant
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
(Date:12/15/2009)... ATLANTA, GADecember 15, 2009Do good-looking people really benefit from ... researchers from the University of Georgia and the University ... to have more social relationships and therefore an increased ... and might be why we spend billions of dollars ... study, published in this month,s issue of Personal ...
(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...
(Date:12/15/2009)... deemed safer than wood fiber , , TUESDAY, Dec. 15 (HealthDay ... arm in a fall are much lower on playgrounds with ... new research has found. , Researchers at the Hospital for ... playground surfaces of either granite sand or engineered wood fiber. ... Medicine . , The risk of a broken arm resulting ...
(Date:12/15/2009)... study finds , , TUESDAY, Dec. 15 (HealthDay News) -- Tight ... with type 2 diabetes who have other medical problems, a ... in type 2 diabetes "has been a subject of controversy ... medicine at the University of California at Irvine, and lead ... the Annals of Internal Medicine . "Our work attempts ...
Breaking Medicine News(10 mins):Health News:First immunological clue to why some H1N1 patients get very ill or die 2Health News:The importance of attractiveness depends on where you live 2Health News:KEMI Renews Contract With PMSI 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 2Health News:Tighter Blood Sugar Control Not Best for Some Diabetics 3
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... and inflammatory diseases,announced today that James S. Burns, ... overview at the Acumen BioFin Rodman & Renshaw ... New York Palace Hotel in,New York, November 5-7, ...
... BPUR ) announced today that the trading symbol ... to BPUR at the open of the market on,Wednesday, ... OTCBB,will revert to the following ticker symbols: BPREW reverting ... BPURL. Biopure Corporation Biopure Corporation develops, manufactures ...
... FRANCISCO, Calif., Oct. 31 Anesiva,Inc. (Nasdaq: ANSV ... chief executive officer, will present at the following events ... November 6, 2007 3:45 p.m. ET ... Healthcare Conference November 27, 2007 4:30 p.m. ...
... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris ... focused on,endocrine therapy and oncology, will announce its ... open on Wednesday, November,7, 2007. The Company will ... results on the same day at 10:00 a.m. ...
... NORTHAMPTON, Mass., Oct. 31 Physicians ... posts to Healthcommunities.com,Inc.,s healthchannels forum,( http://www.healthcommunities.com/health/forums.shtml ... physician post was submitted to the ... hosted and maintained by,Healthcommunities.com, Inc. (HC), ...
... ALTH ), a biopharmaceutical company focused on,the development ... cancer, today announced that Paul L. Berns, President and,CEO, ... BioFin Rodman &,Renshaw Conference in New York. The ... on,Tuesday, November 6, 2007. There will be a live ...
Other Medicine News:Health News:EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference 2Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...
(Date:12/15/2009)... Belgium, Dec. 15 Ghent University Hospital ... world to pioneer radiotherapy treatments using arc therapy, ... and efficient RapidArc radiotherapy technology from Varian Medical ... patient was treated in just 75 seconds, over ... treatments. ,, "This treatment would have taken more ...
Breaking Medicine Technology:Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 1New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 2New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 1Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 2Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 1Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 5
... Nov. 24 A new cancer treatment is,realizing ... treatment, a patient,s large, stage 4 tumor was ... of treatment, it no longer could be definitely,identified ... to nine months,after diagnosis. NeoPlas Innovation,s combination of ...
... moderate to severe acute pain and their health-care providers will ... Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the ... for the relief of moderate to severe acute pain in ... , Tapentadol is a new centrally acting ...
Other Medicine Technology:New Cancer Treatment Shrinks Pancreatic Tumor 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: